COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2020-001891-14-ES


Column Value
Trial registration number EUCTR2020-001891-14-ES
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

First author
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Delos Clinical - Alejandro

Contact
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

secretaria@delosclinical.com

Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2020-05-05

Recruitment status
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Recruiting

Study design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Open label

Center
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

multi-center

Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Treatment

Inclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1. Patients over 18 years old 2. Signature of informed consent 3. Diagnosis by positive PCR for SARS-CoV2 infection 4. They require hospital admission due to fever and other of the established CoV2 admission criteria. 5. Patients with a weight greater than or equal to 60 Kg. 1. Pacientes mayores de 18 años 2. Firma del consentimiento informado 3. Diagnostico mediante PCR positiva por infección de SARS-CoV2 4. Requieran ingreso hospitalario por fiebre persistu otros de los criterios de ingreso establecidos CoV2. 5. Pacientes con peso superior o igual a 60 Kg.

Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1. Allergy to LMWH. 2. Contraindication for anticoagulation (platelets <25 x 10E9 / L or severe active bleeding, major or clinically relevant bleeding) 3. Pregnancy. 4. Patients with extreme weights. BMI greater than 40. 5. Need for chronic anticoagulant treatment. 6. Need for treatment with high-flow oxygen therapy or mechanical ventilation at the time of study recruitment (within the first 24 hours after admission). 7. Participation in another disease treatment trial venous thromboembolic. 1. Alergia a HBPM. 2. Contraindicación para la anticoagulación (plaquetas < 25 x 10E9/L o sangrado activo grave, hemorragia mayor o clínicamente relevante) 3. Embarazo. 4. Pacientes con pesos extremos. IMC mayor a 40. 5. Necesidad de tratamiento anticoagulante crónico. 6. Necesidad de tratamiento con oxigenoterapia a alto flujo o ventilación mecánica en el momento del reclutamiento en el estudio (dentro de las primeras 24h tras el ingreso). 7. Participación de otro ensayo de tratamiento de la enfermedad tromboembólica venosa.

Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Fundación Neumosur

Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

None

Countries
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Spain

Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Moderate disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

3: Moderate disease at enrollment

Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

140

primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Need for oxygen therapy escalation due to oxygen saturation (Sat O2) ≤92% with inspired fraction of oxygen (FiO2) ≥0.5 and respiratory rate (FR) ≥30 (IROX index = SatO2 / FiO2] / FR <5.5) or invasive mechanical ventilation or mortality during admission. Necesidad de escalada de oxigenoterapia por saturación de oxígeno (Sat O2) ≤92% con fracción inspirada de oxígeno (FiO2) ≥0,5 y frecuencia respiratoria (FR) ≥30 (Indice IROX=SatO2/FiO2]/FR < 5.5) o ventilación mecánica invasiva o mortalidad durante el ingreso.

Notes
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Declared number of arm (2.0) differs from found arms (1.0)

Phase
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Phase 2

Arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

[{"arm_notes": "prophylactic doses", "treatment_id": 463, "treatment_name": "Enoxaparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "intermediate doses", "treatment_id": 463, "treatment_name": "Enoxaparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}]